Page 55 - Read Online

Balakrishnan et al. J Cancer Metastasis Treat 2022;8:27 https://dx.doi.org/10.20517/2394-4722.2022.33 Page 15 of 17

57. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:958-69. DOI PubMed
PMC
58. Pang Y, Gara SK, Achyut BR, et al. TGF-β signaling in myeloid cells is required for tumor metastasis. Cancer Discov 2013;3:936-
51. DOI PubMed PMC
59. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation
and polarization. Trends Immunol 2004;25:677-86. DOI PubMed
60. Cassetta L, Fragkogianni S, Sims AH, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal
cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell 2019;35:588-602.e10. DOI PubMed PMC
61. Xu J, Chi F, Guo T, et al. NOTCH reprograms mitochondrial metabolism for proinflammatory macrophage activation. J Clin Invest
2015;125:1579-90. DOI PubMed PMC
62. Wang YC, He F, Feng F, et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune
responses. Cancer Res 2010;70:4840-9. DOI PubMed
63. Shen Q, Cohen B, Zheng W, et al. Notch shapes the innate immunophenotype in breast cancer. Cancer Discov 2017;7:1320-35. DOI
PubMed
+
64. Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS /M1 phenotype that
orchestrates effective T cell immunotherapy. Cancer Cell 2013;24:589-602. DOI PubMed
65. Liechtenstein T, Perez-Janices N, Gato M, et al. A highly efficient tumor-infiltrating MDSC differentiation system for discovery of
anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget 2014;5:7843-57. DOI PubMed
PMC
66. Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to
T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014;74:5057-69. DOI PubMed PMC
67. DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 2019;19:369-82.
DOI PubMed PMC
68. Bronte V, Brandau S, Chen SH, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization
standards. Nat Commun 2016;7:12150. DOI PubMed PMC
69. Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev
Immunol 2021;21:485-98. DOI PubMed PMC
70. Salminen A, Kaarniranta K, Kauppinen A. Immunosenescence: the potential role of myeloid-derived suppressor cells (MDSC) in
age-related immune deficiency. Cell Mol Life Sci 2019;76:1901-18. DOI PubMed PMC
71. Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell
subpopulations with distinct T cell-suppressive activity. Blood 2008;111:4233-44. DOI PubMed
72. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest
2015;125:3356-64. DOI PubMed PMC
73. Kiss M, Van Gassen S, Movahedi K, Saeys Y, Laoui D. Myeloid cell heterogeneity in cancer: not a single cell alike. Cell Immunol
2018;330:188-201. DOI PubMed
74. Parker KH, Beury DW, Ostrand-rosenberg S. Myeloid-derived suppressor cells. Adv Cancer Res 2015;128:95-139. DOI PubMed
PMC
75. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell
2012;21:309-22. DOI PubMed
76. Meyer C, Cagnon L, Costa-Nunes CM, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients
treated with ipilimumab. Cancer Immunol Immunother 2014;63:247-57. DOI PubMed
77. Sade-Feldman M, Kanterman J, Klieger Y, et al. Clinical significance of circulating CD33+CD11b+HLA-DR- myeloid cells in
patients with stage IV melanoma treated with ipilimumab. Clin Cancer Res 2016;22:5661-72. DOI PubMed
78. Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat
Med 2015;21:938-45. DOI PubMed PMC
79. Guruharsha KG, Kankel MW, Artavanis-Tsakonas S. The Notch signalling system: recent insights into the complexity of a conserved
pathway. Nat Rev Genet 2012;13:654-66. DOI PubMed PMC
80. Sierra RA, Trillo-Tinoco J, Mohamed E, et al. Anti-Jagged immunotherapy inhibits MDSCs and overcomes tumor-induced tolerance.
Cancer Res 2017;77:5628-38. DOI PubMed PMC
81. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in
enhanced T cell-dependent antitumor immunity. Cancer Res 2010;70:3052-61. DOI PubMed
82. Highfill SL, Cui Y, Giles AJ, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl
Med 2014;6:237ra67. DOI PubMed PMC
83. Dominguez C, McCampbell KK, David JM, Palena C. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces
mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight 2017;2:94296. DOI PubMed PMC
84. Damin DC, Lazzaron AR. Evolving treatment strategies for colorectal cancer: a critical review of current therapeutic options. World J
Gastroenterol 2014;20:877-87. DOI PubMed PMC
85. Urruticoechea A, Alemany R, Balart J, Villanueva A, Viñals F, Capellá G. Recent advances in cancer therapy: an overview. Curr
Pharm Des 2010;16:3-10. DOI PubMed